|本期目录/Table of Contents|

[1]聂燕,丁洪成,朱名洁,等.达格列净对门冬胰岛素30治疗血糖控制不达标的超重或肥胖2型糖尿病患者的疗效和安全性研究[J].慢性病学杂志,2021,(02):182-186.
　NIEYan *,DINGHong-cheng,ZHUMing-jie,et al.Effectiveness and safety of dapagliflozin on substandard glycemic control of overweight or obesity type2diabetic patients treated with insulin aspart30[J].,2021,(02):182-186.
点击复制

达格列净对门冬胰岛素30治疗血糖控制不达标的超重或肥胖2型糖尿病患者的疗效和安全性研究

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2021年02期
页码:
182-186
栏目:
论　著
出版日期:
2021-01-20

文章信息/Info

Title:
Effectiveness and safety of dapagliflozin on substandard glycemic control of overweight or obesity type2diabetic patients treated with insulin aspart30
作者:
聂燕1; 丁洪成2 ;  朱名洁2; 李艳丽2; 汪茜2; 刘诗苑1
1.锦州医科大学十堰市人民医院研究生培养基地，湖北 十堰 442000； 2.湖北医药学院附属人民医院内分泌科，湖北 十堰 442000
Author(s):
NIEYan * ; DINGHong-cheng; ZHUMing-jie; LIYan-li; WANGQian; LIUShi-yuan
*PostgraduateTrainingBase ofJinzhouMedicalUniversity,DepartmentofEndocrinology, RenminHospital, HubeiUniversityofMedicine,Shiyan,Hubei442000,China Correspondingauthor:DINGHong-cheng,E-mail:121983113@qq.com
关键词:
达格列净; 2型糖尿病; 超重; 肥胖; 疗效; 安全性
Keywords:
Dapagliflozin;  Type2 diabetes mellitus;  Overweight;  Obesity;  Effectiveness;  Safety
分类号:
R587.1
DOI:
-
摘要:
目的 探讨达格列净对门冬胰岛素30治疗血糖控制不达标的超重或肥胖2型糖尿病（T2DM）患者的疗 效和安全性。方法 选取2018年10月至2019年7月十堰市人民医院内分泌科就诊的应用门冬胰岛素30治疗血 糖控制不达标的48例超重或肥胖型T2DM患者作为研究对象，采用随机数字表法分为观察组和对照组，每组 24例。对照组采用门冬胰岛素30联合口服传统降糖药物，观察组在对照组降糖方案基础上联用达格列净10 mg 治疗，连续治疗12周后比较治疗前后两组综合指标控制情况。结果 治疗12周后，两组空腹血糖（FPG）、餐 后2 h血糖（2hPG）、糖化血红蛋白（HbA1c）、体质量指数（BMI)、血压、尿酸、胰岛素剂量等指标比较，差异 有统计学意义（P<0.05）。两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论 使用门冬胰岛素30 控制不达标的超重或肥胖T2DM患者联合使用达格列净，可显著降低患者血糖、BMI，减少胰岛素剂量，同时有 一定的降压、降尿酸作用，不良反应发生率相对传统降糖药物较低，安全性较高。
Abstract:
Objective To investigate the effectiveness and safety of dapagliflozin for patients with over-weight or obesity type2 diabetes mellitus（T2DM）who have poor glycemic control.Methods Forty-eight cases of overweight or obesity T2DM patients who were accepted the treatment of biphasic insu-lin aspart 30 with substandard blood glucose control were enrolled from the Department of Endocrinolo-gy, Shiyan People’s Hospital from September 2018 to June 2019. According to the random number ta-ble method, all patients were divided into the experimental group and the control group. The control group was treated with insulin aspart 30 combined with oral traditional hypoglycemic drugs, and the observation group was treated with dapagliflozin 10 mg on the basis of the hypoglycemic regimen of the control group. After 12 weeks of continuous treatment, the comprehensive index control of the two groups before and after treatment was compared. Results After12 weeks of treatment, there were statistically significant differences in HbA1c, FPG, 2hPG, BMI, blood pressure, uric acid and insulin dose between the two groups（P<0.05）. There was no significant difference in the incidence of ad-verse reactions between the two groups（P>0.05）. Conclusion Foroverweight or obesity T2DM pa-tients who fail to reach the standard controlled by biphasic insulin aspart 30, combined use of dapa-gliflozin can significantly reduce the patient’s blood glucose, BMI, and insulin dose. At the same time, it has a certain effect of lowering blood pressure and uric acid with relatively lower incidence of adverse reactions and higher safety.

参考文献/References:

[1] LI Y, TENG D, SHI X,et al. Prevalence of diabetes re-corded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study [J]. BMJ, 2020,369:m997. [2] 蒋建家,张雅萍,牟伦盼,等.达格列净对预混胰岛素治疗血糖控 制不达标的2型糖尿病患者的疗效和安全性研究[J].中国糖尿病 杂志,2018,26(12):31-35. [3] Listed N. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999 [J]. Diabet Med, 1999,16(9):716. [4] 纪立农,陆菊明,郭晓蕙,等.中国2型糖尿病药物治疗现状与血糖 控制的调查研究[J].中华糖尿病杂志,2012,4(7):397-401. [5] 郑娟,廖庆红,何纯.诺和锐30治疗肥胖2型糖尿病患者疗效观察 [J].中国慢性病预防与控制,2008,16(6):628. [6] 牟伦盼,蒋建家,张雅萍,等.达格列净与利格列汀对口服降糖药 控制不佳的超重或肥胖2型糖尿病患者的疗效和安全性比较[J]. 中华糖尿病杂志,2019,11(3):190-195. [7] Wilding JPH, Woo V, Rohwedder K,et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of in-sulin: efficacy and safety over 2 years [J]. Diabetes Obes Metab,2014,16(2):124-136. [8] 甄霞,顾红燕,文祯,等.达格列净联合胰岛素治疗特定2型糖尿病 住院患者的疗效与安全性分析[J].中国医院药学杂志,2019,39 (4):385-389. [9] 陈晓蕾,贾农,杨林,等.胰岛素治疗血糖控制不佳的2型糖尿病患 者联合达格列净的疗效及安全性[J].糖尿病新世界,2017,20(22): 64-66. [10] Kohan DE, Fioretto P, Tang W,et al. Long-term study of patients with type 2 diabetes and moderate renal impair-ment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control [J]. Kidney Int, 2014,85(4):962-971. [11] Weber MA, Mansfield TA, Cain VA,et al. Blood pres-sure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihyper-tensive therapy: a randomised, double-blind, placebo-con-trolled, phase 3 study [J]. Lancet Diabetes Endocrinol, 2016,4(3):211-220. [12] Hao Z, Huang X, Shao H,et al. Effects of dapagliflozin on serum uric acid levels in hospitalized type2 diabetic pa-tients with inadequate glycemic control: a randomized con-trolled trial [J]. Ther Clin Risk Manag, 2018,14:2407-2413. [13] Li D, Wang T, Shen S,et al. Urinary tract and genital infections in patients with type 2 diabetes treated with so-dium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials [J]. Diabetes Obes Metab, 2017,19(3):348-355. [14] Mathieu C, Dandona P, Gillard P,et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Con-trolled Type 1 Diabetes (the DEPICT-2 Study):24-Week Results From a Randomized Controlled Trial [J]. Diabetes Care,2018,41(9):1938-1946.

备注/Memo

备注/Memo:
基金项目：十堰市科学技术局科研项目（18Y68） 作者简介：聂燕，住院医师，硕士研究生，研究方向：内分泌代谢学 通信作者：丁洪成，E-mail:121983113@qq.com
更新日期/Last Update: 2021-02-28